Neurohospitalist, Director of Stroke, @UHC_WV, Assistant Professor of Neurology, @WVUMedschool; @strokemiami; @brownneurology

Miami, FL
Joined August 2018
Daniel Mandel, MD retweeted
For the love of God, please start flossing regularly
41
183
20
1,372
88,039
Daniel Mandel, MD retweeted
GLP-1 drugs have changed the face of weight loss. But amid high prices and obstacles to access, people are attempting experimental small doses. Are the drugs effective at these doses—and is microdosing GLP-1s safe? bmj.com/content/395/bmj-2026…
14
22
2
103
27,620
Daniel Mandel, MD retweeted
RCT of IVIG for #Sjogrens painful sensory neuropathy showed significantly reduced pain and improved patient function after 3 rounds of IVIG at 11 weeks: Paris International Sjogrens Symposium …. Nice to see more evidence and this is what my patients report after tx
3
31
2
111
5,081
Daniel Mandel, MD retweeted
The list of GLP-1 drug benefits independent of weight loss keep growing
Direct benefits of semaglutide/GLP-1 on the kidney in patients with Type 2 diabetes and chronic kidney disease, a placebo-randomized mechanistic trial. Reduction of inflammation and prevention of fibrosis. nature.com/articles/s41591-0…
66
324
34
1,868
321,817
Daniel Mandel, MD retweeted
Israeli passenger that was on the @flydubai flight to Israel gives a perfect testimony. No need to translate, just watch
72
253
64
2,521
641,000
Daniel Mandel, MD retweeted
Original Article: Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (SINGLE-AF trial) nej.md/4ii61XB Editorial: Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke nej.md/45FR7D4 #Cardiology #ESCCongress
4
45
145
34,555
Daniel Mandel, MD retweeted
People saying "I'd never give Muse/Meta access to my Gmail, Calendar, etc" is the 2026 version of "I'll never put my credit card on the internet."
113
89
29
1,864
76,900
Daniel Mandel, MD retweeted
I wish someone would listen. I’ve been warning about @UHC’s erroneous "prediction" AI tool, developed by NaviHealth, for three years now: fixhealth.ai/i/139288387/17-… Perhaps not coincidentally, @iamjohnoliver talked at length about $UNH’s questionable practices on his show tonight, including upcoding and this crazily error-prone AI tool by naviHealth.
3
10
15
806
Daniel Mandel, MD retweeted
Radiology used to have something that was almost invisible because it was so routine: The reading room consult. Rounding teams came down. Surgeons pulled up their cases. Internists brought the scan that didn't quite fit the clinical picture. Sometimes the radiologist solved the problem. Sometimes the clinician supplied one piece of history that completely changed how the images were interpreted. And usually everyone simply walked away a little sharper. But something else was happening during all of those conversations. We were learning each other. As a radiologist, I learned what individual physicians cared about. I knew which findings mattered to a particular surgeon. Which measurements an oncologist was following. Which details a specialist wanted emphasized. What questions they were really asking, even when the order just said "pain." And they learned me. They knew who was reading their study. They knew they could walk in, point at something, challenge an interpretation, or ask, "What do you think?" That relationship created context. It created feedback. It created trust. And over years, it created a kind of institutional knowledge that never appears in the medical record. When radiology becomes a report produced by someone hundreds or thousands of miles away, we don't just lose proximity. We risk losing that entire feedback loop. The report may still be technically excellent. But the radiologist knows less about the physician. The physician knows less about the radiologist. The radiologist sees less of what happened after the report. And both sides lose opportunities to make each other better. The reading room was never just a room. It was where imaging became part of the clinical conversation. We should think very carefully before designing that conversation out of medicine. Inspired by a conversation yesterday with @PaleoOnc . Also @909One and @brianchiong .
131
210
58
1,142
184,305
Daniel Mandel, MD retweeted
🧵 Among patients with asymptomatic high-grade internal #carotid artery stenosis and reduced cognition at baseline, carotid revascularization plus intensive medical management did not improve cognitive outcomes vs intensive medical management alone over 1 year. Baseline cerebral hemodynamic impairment did not modify this result, indicating that restoring flow to the brain should not be expected to improve cognition in chronic asymptomatic carotid stenosis. ja.ma/4rhzaok
4
23
1
87
14,970
Daniel Mandel, MD retweeted
🚨 FDA approves the first oral treatment for adult dermatomyositis Brepocitinib (Lisraya) - an oral TYK2/JAK1 inhibitor is now FDA-approved for the treatment of dermatomyositis in adults. 🔹 First FDA-approved oral therapy specifically indicated for adult dermatomyositis 🔹 Provides a new targeted treatment option for this rare autoimmune disease 🔹 Approval follows clinical-trial evidence demonstrating improvement in disease activity A significant development in the therapeutic landscape of dermatomyositis. 🧬 #Dermatomyositis #Brepocitinib #Rheumatology #Myositis #RheumattDoc #MedTwitter #RheumTwitter #Medicine @docakx @IhabFathiSulima @CelestinoGutirr @DurgaPrasannaM1
🧵 VALOR Phase 3 trial Brepocitinib (TYK2/JAK1 inhibitor) shows promising results in active Dermatomyositis 1/ Study design • n=241, 20 countries • Active skin (CDASI ≥6) + muscle (MMT-8 ≤142) • BREPO 30 mg / 15 mg vs placebo (52 weeks) • Background SOC allowed + steroid taper 2/ Primary outcome ✔️ BREPO 30 mg met primary endpoint • TIS: 46.5 vs 31.2 (placebo) • Δ +15.3 (p=0.0006) 3/ Key findings • Rapid response (by Week 4) • Benefit across skin + muscle + QOL • Dose-dependent efficacy • All major secondary endpoints met 4/ Steroid sparing 💊 At 12 months (BREPO 30 mg): • 62% → ≤2.5 mg/day • 42% → off steroids (Placebo: 34% & 23%) 5/ Safety Consistent with prior studies → favorable benefit–risk profile 6/ Why this matters 🔹 First positive Phase 3 RCT of an oral targeted therapy in DM 🔹 Largest & longest trial in this space 👉 Brepocitinib 30 mg could be a game-changer in DM management #RheumattDoc #MedTwitter #Dermatomyositis #RheumTwitter #Medicine #rheumatology @DrAkhilX @IhabFathiSulima @CelestinoGutirr @DurgaPrasannaM1
5
1
12
5,092
💬 Editorial Insight: A Tantalizing Prospect in Stroke Care 🧠 Dr. Jeffrey Saver’s JAMA editorial contextualizes the LAIS trial results, noting that while reperfusion therapies are reaching their limits, neuroprotective strategies may finally be yielding results. Key perspectives from the editorial: 👉 Dual-action potential: Loberamisal combines neuroprotective and neuroreparative mechanisms across prereperfusion, postreperfusion, and recovery phases. 👉 Practical window: The 48-hour treatment window accommodates the large proportion of stroke patients who arrive too late for reperfusion therapy. 👉 Scientific caution: The trial defies historical paradigms with a treatment effect size comparable to early thrombolysis, calling for thoughtful evaluation. 👉 Call for replication: Because extraordinary claims require extraordinary evidence, independent multinational trials and participant-level data sharing are critical next steps. Reference: Saver JL. Neuroprotective Therapy for Acute Ischemic Stroke: A Tantalizing Prospect. JAMA. Published online September 10, 2026. doi:10.1001/jama.2026.17400 doi.org/10.1001/jama.2026.17…
1
1
137
🚨 IV Loberamisal for Acute Ischemic Stroke Neuroprotection within 48hrs 🧠 The Phase 3 LAIS Trial was just published, evaluating intravenous loberamisal for patients with acute ischemic stroke treated within 48 hours of symptom onset. Key findings at 90 days: ✅ 69.7% of the loberamisal group achieved full functional recovery (mRS 0-1) compared to 56.3% on placebo. ✅ The treatment was safe, with no increase in serious adverse events or mortality. This novel drug dually targets the PSD-95 pathway and the α2-GABAA receptor, offering a promising neuroprotective strategy to complement standard stroke care. Reference: Li S, Feng B, He D, et al. Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial. JAMA. Published online September 10, 2026. doi:10.1001/jama.2026.16557. doi.org/10.1001/jama.2026.16…
2
10
34
2,066
Daniel Mandel, MD retweeted
🧠 When turning the head causes a stroke… think beyond the brain. A fascinating case of Bow Hunter Syndrome (rotational vertebral artery occlusion): 🔹 Recurrent posterior circulation strokes 🔹 Occipitalization of C1 🔹 C1–C2 bony anomaly with an osteophyte at the C2 transverse foramen 🔹 Routine static angiography was inconclusive 🔹 Dynamic cerebral angiography clinched the diagnosis 🎯 The patient was asked to turn the head to the LEFT. Injection of the right occipital artery demonstrated dynamic compression of the vertebral artery at the C2 transverse foramen. The key lesson: The culprit may only appear when the head moves. In patients with recurrent posterior circulation ischemia + reproducible neck pain/neurological symptoms with rotation, dynamic vascular imaging can be diagnostic—and potentially stroke-preventing. #BowHunterSyndrome #VertebralArtery #Stroke #Neurointervention #Neuroradiology #DynamicDSA #PosteriorCirculationStroke
7
67
9
278
44,271
Daniel Mandel, MD retweeted
Replying to @ajlees
Correction. Seven (7) trials of "preclinical AD". Two resulted in futility; 5 showed onset of clinical decline in the treated arm vs. placebo. There will likely be more. Neurologists don't take 'No' for an answer from most trials.
4
7
41
1,572
Daniel Mandel, MD retweeted
Statins can reduce dementia risk by up to 15%, long-term study suggests: theguardian.com/society/2026… The findings were presented at the 2026 congress of the European Society of Cardiology (ESC), and simultaneously published in the Lancet Reg Health Eur: thelancet.com/journals/lanep…
24
51
13
218
43,373
Daniel Mandel, MD retweeted
Original Article: Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults (STAREE trial) nej.md/4ghHPSC #ESCCongress | @escardio
1
31
4
120
35,276